Clinical Trial Update: Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating nivolumab combined with anlotinib as re-challenge therapy in advanced non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• nivolumab (nivolumab)

Snippet

Sponsor: Shanghai Chest Hospital | Conditions: NSCLC Stage IV, Checkpoint Inhibitor | Phase 1, Phase 2 | Status: COMPLETED